Worm-Fighting combo pill tested in kids, but trial stopped early
NCT ID NCT05124691
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new pill combining two drugs (albendazole and ivermectin) to treat several types of intestinal worms in children and young adults aged 5 to 18. The goal was to see if the combination worked better than the standard single drug. However, the trial was terminated early, so the planned results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
albendazole and ivermectin combination pill
What this could lead to
If it had succeeded, this combination could have offered a more effective single treatment for several types of intestinal worms, especially those resistant to current drugs.
What could go wrong
The trial was terminated, so we don't have full results. Early-stage research often fails to show benefit or may reveal safety issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRICHURIS TRICHIURA; INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bahir Dar University, Colleges of Medicine and Health Sciences (BDU-CMHS)
Bahir Dar, P.O. Box 79, Ethiopia
-
Centro de Investigação em Saúde da Manhiça (CISM)
Manhiça, Maputo Province, 1929, Mozambique
-
Kenya Medical Research Institute (KEMRI)
Nairobi, 54840-00200, Kenya